Mineralys Therapeutics, Inc. (MLYS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on the stock and has a $33.00 price target.
Rami Katkhuda’s rating is based on the promising potential of Mineralys Therapeutics, Inc.’s lead compound, lorundrostat, in addressing unmet needs in hypertension treatment. The insights from a key opinion leader (KOL) highlight the significant role of aldosterone synthase inhibitors (ASIs) in managing hypertension, especially in cases where excess aldosterone is a factor. The KOL is optimistic about lorundrostat’s ability to achieve meaningful reductions in systolic blood pressure, which could position it as a valuable treatment option.
Furthermore, the potential market opportunity is underscored by the expectation that up to 25% of resistant hypertensive patients could be treated with ASIs if approved. The possibility of lorundrostat being used in earlier lines of treatment, particularly in specific patient subgroups, adds to the positive outlook. These factors combined with the current poor control rates of blood pressure despite available treatments, suggest a strong market potential for Mineralys Therapeutics, Inc., justifying the Buy rating.
In another report released on February 25, Stifel Nicolaus also reiterated a Buy rating on the stock with a $45.00 price target.